Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Total Non-Current Liabilities (2016 - 2025)

Angiodynamics (ANGO) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $76.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 138.41% year-over-year to $76.3 million, compared with a TTM value of $76.3 million through Nov 2025, up 138.41%, and an annual FY2025 reading of $80.3 million, down 16.39% over the prior year.
  • Total Non-Current Liabilities was $76.3 million for Q4 2025 at Angiodynamics, up from $72.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $149.8 million in Q2 2023 and bottomed at -$218.7 million in Q1 2024.
  • Average Total Non-Current Liabilities over 5 years is $59.5 million, with a median of $103.2 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities tumbled 436.35% in 2024, then skyrocketed 138.41% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $114.0 million in 2021, then grew by 28.7% to $146.7 million in 2022, then plummeted by 32.95% to $98.4 million in 2023, then crashed by 301.9% to -$198.6 million in 2024, then surged by 138.41% to $76.3 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ANGO at $76.3 million in Q4 2025, $72.6 million in Q3 2025, and $80.3 million in Q2 2025.